Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0650-0013 first-in-human dose study in healthy males
NCT06284798Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2024
- Primary completion
- Jul 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NNC0650-0013 in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Novo Nordisk. Primary endpoint: Treatment Emergent Adverse Events at 75 days. Started Jan 2024; status: completed.
02
Drugs
NNC0650-0013
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06284798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06284798.